in the NR«Prometic also intends to initiate a second phase 2/3 placebo-controlled trial which would enroll IPF patients who have failed to tolerate nintedanib or pirfenidone.»
I think this part is also interesting.
If you go to the blogs of some organism about IPF , you can see that 90% of the talks in those blogs is about the sides effects of the 2 drugs and that the patients switch from one to the other to try to tolerate the sides effects.
Those patients will choose at first, the results on there immediate wealth from the first days , well before the long term results , it's natural .What i see from those blogs is that pbi4050 can became the choice for those already in bad condition.